BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

question and answer session. If you would like to ask a question, press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements. For our discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference. Good afternoon, everyone, and thank you for joining BridgeBio Pharma's second quarter 2025 earnings call. I'm Chinmay Shukla, Senior Vice President of Strategic Finance at BridgeBio. With me today are Neel Kumar, our CEO, Matt Outen, our Chief Commercial Officer, and Tom Trimarchi, our President and Chief Financial Officer. During today's call, we will cover our strong and accelerating launch of a Truby. We will provide updates on our late-stage pipeline, including the three key phase three trials in ADH1, LGMD2I, and Acon Reclasia. Following our prepared remarks, we will open the call for questions. F...